Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Intangibles (2019 - 2025)

Harmony Biosciences Holdings' Intangibles history spans 7 years, with the latest figure at $215.0 million for Q3 2025.

  • For Q3 2025, Intangibles changed 0.0% year-over-year to $215.0 million; the TTM value through Sep 2025 reached $215.0 million, changed 0.0%, while the annual FY2024 figure was $215.0 million, 56.81% up from the prior year.
  • Intangibles for Q3 2025 was $215.0 million at Harmony Biosciences Holdings, roughly flat from $215.0 million in the prior quarter.
  • Across five years, Intangibles topped out at $215.0 million in Q3 2023 and bottomed at $137.1 million in Q4 2023.
  • The 5-year median for Intangibles is $215.0 million (2023), against an average of $186.9 million.
  • The largest annual shift saw Intangibles dropped 17.76% in 2021 before it soared 56.81% in 2024.
  • A 5-year view of Intangibles shows it stood at $143.9 million in 2021, then rose by 11.84% to $161.0 million in 2022, then fell by 14.81% to $137.1 million in 2023, then skyrocketed by 56.81% to $215.0 million in 2024, then changed by 0.0% to $215.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Intangibles are $215.0 million (Q3 2025), $215.0 million (Q4 2024), and $215.0 million (Q3 2024).